Sugi Predict

Sugi Predict / Targets / MAPKAPK2

MAPKAPK2

MAP kinase-activated protein kinase 2 · P49137 · MAPKAPK2 on Sugi Atlas →

86,994 patent compounds predicted against MAPKAPK2, 52,997 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL261816 SCHEMBL261816 0.44 12/20
SCHEMBL273473 SCHEMBL273473 0.67 7/20
SCHEMBL78108 SCHEMBL78108 0.49 6/20
SCHEMBL56219 SCHEMBL56219 0.44 6/20
SCHEMBL272856 SCHEMBL272856 0.41 6/20
SCHEMBL88260 SCHEMBL88260 0.53 5/20
SCHEMBL376258 SCHEMBL376258 0.50 5/20
SCHEMBL78493 SCHEMBL78493 0.46 5/20
SCHEMBL64988 SCHEMBL64988 0.43 5/20
SCHEMBL12222 SCHEMBL12222 0.56 4/20
SCHEMBL231077 SCHEMBL231077 0.52 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL376202) 0.51 4/20
SCHEMBL330953 SCHEMBL330953 0.43 4/20
SCHEMBL164105 SCHEMBL164105 0.42 4/20
SCHEMBL376298 SCHEMBL376298 0.42 4/20
SCHEMBL273395 SCHEMBL273395 0.41 4/20
Adrenoglomerulotropin Adrenoglomerulotropin (SCHEMBL356345) 0.67 3/20
SCHEMBL218021 SCHEMBL218021 0.55 3/20
SCHEMBL12136 SCHEMBL12136 0.50 3/20
SCHEMBL272916 SCHEMBL272916 0.50 3/20

Clinical trials — most relevant to MAPKAPK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies PHASE1/PHASE2RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma nanCOMPLETED
Glutamate Supplementation in Young Men nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MAPKAPK2 binder may also engage these)

ProteinNameSimilarity
P49138 — 0.998 P49138 →
P49139 — 0.997 P49139 →
MAPKAPK3 MAP kinase-activated protein kinase 3 0.987 landscape →
Q66H84 — 0.984 Q66H84 →
Q3UMW7 — 0.982 Q3UMW7 →
Q3SYZ2 — 0.980 Q3SYZ2 →
Q7XQP4 — 0.973 Q7XQP4 →
Q9FFP9 — 0.971 Q9FFP9 →
P49136 — 0.970 P49136 →
Q6ZI44 — 0.969 Q6ZI44 →
Q75H77 — 0.969 Q75H77 →
O88506 — 0.969 O88506 →
A2YNT8 — 0.968 A2YNT8 →
Q0D4J7 — 0.968 Q0D4J7 →
A9TF79 — 0.967 A9TF79 →
A0A8I5ZNK2 — 0.967 A0A8I5ZNK2 →
Q6P9R2 — 0.967 Q6P9R2 →
Q863I2 — 0.966 Q863I2 →
P43292 — 0.966 P43292 →
Q9Z1W9 — 0.965 Q9Z1W9 →
Q9C958 — 0.965 Q9C958 →
P43291 — 0.965 P43291 →
STK39 STE20/SPS1-related proline-alanine-rich protein kinase 0.963 landscape →
Q5N942 — 0.963 Q5N942 →
Q75LR7 — 0.963 Q75LR7 →
Q940H6 — 0.962 Q940H6 →
A2ZAB5 — 0.960 A2ZAB5 →
P0C5D6 — 0.960 P0C5D6 →
AKT1 RAC-alpha serine/threonine-protein kinase 0.959 landscape →
Q8JH47 — 0.959 Q8JH47 →